Basics Agenus Inc. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer. IPO Date: February 4, 2000 Sector: Healthcare Industry: Biotech Market Cap: $140.84M Activated in VL: True Average Daily Range Avg Daily Range: $0.12 | 3.44% Avg Daily Range (30 D): $0.14 | 3.18% Avg Daily Range (90 D): $0.19 | 3.89% Institutional Daily Volume Avg Daily Volume: 1.4M Avg Daily Volume (30 D): .45M Avg Daily Volume (90 D): .66M Trade Size Avg Trade Size (Sh.): 276 Avg Trade Size (Sh.) (30 D): 120 Avg Trade Size (Sh.) (90 D): 129 Institutional Trades Total Inst.Trades: 1,260 Avg Inst. Trade: $1.65M Avg Inst. Trade (30 D): $.64M Avg Inst. Trade (90 D): $1.88M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.76M Avg Closing Trade (30 D): $.64M Avg Closing Trade (90 D): $2.71M Avg Closing Volume: 38.91K     News Aug 28, 2025 @ 2:44 PM FDA Tightens Survival Standards as Cancer Drug Pip... Source: Prnewswire Aug 18, 2025 @ 5:00 PM PD-(L)1 Inhibitors Market Set to Surge During the ... Source: Delveinsight Aug 13, 2025 @ 2:00 PM U.S. Pharmaceutical CDMO Market Valuation to Surpa... Source: Towards Healthcare Jul 29, 2025 @ 7:46 PM Biotech Underdogs Line Up for Pivotal Shots at Gam... Source: Prnewswire Jun 13, 2025 @ 1:48 PM Neoantigen Cancer Vaccines Industry Analysis Repor... Source: Researchandmarkets.Com Financials   TTM Q2 2025 Q1 2025 Basic EPS $-7.05 $-1 $-1.03 Diluted EPS $-7.05 $-1 $-1.03 Revenue $ 101.71M $ 25.69M $ 24.07M Gross Profit $ 101.06M $ 25.45M $ 23.93M Net Income / Loss $ -170.4M $ -30.01M $ -26.37M Operating Income / Loss $ -87.42M $ -16.71M $ -13.31M Cost of Revenue $ .64M $ .24M $ .14M Net Cash Flow $ -83.95M $ $ PE Ratio     Splits Apr 12, 2024:   1:20 Oct 03, 2011:   1:6